Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.78 |
| ▸ | DRD1 | P21728 | 2/20 | 0.78 |
| ▸ | DRD3 | P35462 | 5/20 | 0.57 |
| ▸ | DRD4 | P21917 | 3/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | DRD5 | P21918 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7781196 | 1.00 | DRD2 (0.78) | DRD2DRD1DRD3DRD4HTR1A | |
| Hexanoate SCHEMBL7790202 | 0.90 | DRD2 (0.62) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL7362530 | 0.88 | DRD2 (1.00) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL7788774 | 0.88 | DRD2 (1.00) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL7788379 | 0.86 | DRD2 (0.81) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL7781190 | 0.86 | DRD2 (0.81) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL7781207 | 0.85 | DRD2 (0.80) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL8742154 | 0.85 | DRD2 (0.80) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL7785685 | 0.84 | DRD2 (0.78) | DRD2DRD1DRD3DRD4HTR1A | |
| SCHEMBL7788407 | 0.84 | DRD2 (0.78) | DRD2DRD1DRD3DRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | disclosed |
| EP-0717620-B1 | SUBSTITUTED 2-AMINOTETRALINS | DISCOVERY THERAPEUTICS INC (US) | 2001-10-31 | — | — | EP | disclosed |
| US-5382596-A | Useful for alleviating Parkinsonism, glaucoma, hyperprolactinemia and for inducing weight loss in mammals | WHITBY RESEARCH, INC. (US) | 1995-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | CHRM2, ADRB2, CHRM3 | DRD2 33/4885DRD1 61/4885DRD3 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.